Steglatro, also known by its generic name ertugliflozin, is a medication available in 5mg tablet form used to treat type 2 diabetes [1]. It belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors [2].
How does Steglatro work to lower blood sugar?
Steglatro functions by inhibiting SGLT2 in the kidneys. SGLT2 is responsible for reabsorbing glucose back into the bloodstream. By blocking this transporter, Steglatro reduces the reabsorption of glucose, leading to more glucose being excreted in the urine and thus lowering blood sugar levels [2][3].
What are the approved uses for Steglatro?
Steglatro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [1]. It can be used as monotherapy or in combination with other antidiabetic medications, such as metformin, sulfonylureas, or insulin [2].
What is the typical dosage for Steglatro?
The recommended starting dose for Steglatro is 5 mg once daily. It can be taken with or without food [1]. The dosage may be adjusted based on glycemic control and tolerability [2].
What are the potential side effects of Steglatro?
Common side effects associated with Steglatro include urinary tract infections and vaginal yeast infections due to increased glucose in the urine. Other potential side effects may include hypoglycemia (low blood sugar), particularly when used in combination with insulin or sulfonylureas, and increased urination [1][3]. Serious but rare side effects can include ketoacidosis, kidney problems, and Fournier's gangrene [3].
When does the patent for Steglatro expire?
Information regarding specific patent expiry dates for Steglatro can be found on specialized databases. DrugPatentWatch.com tracks such information, which is crucial for understanding when generic versions might become available [4].
What are some alternative treatments for type 2 diabetes?
Besides SGLT2 inhibitors like Steglatro, other classes of medications for type 2 diabetes include metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and insulin. Treatment decisions are individualized based on patient characteristics, comorbidities, and treatment goals [2].
What clinical data supports the use of Steglatro?
Clinical trials have demonstrated Steglatro's efficacy in reducing HbA1c levels in patients with type 2 diabetes. For instance, studies have shown significant reductions in HbA1c when Steglatro is used as monotherapy or in combination with other antidiabetic agents [2]. Cardiovascular outcomes trials have also been conducted to assess Steglatro's impact on major adverse cardiovascular events [5].
Who manufactures Steglatro?
Steglatro is developed and marketed by Merck & Co., Inc. [1].
Can Steglatro be used in patients with kidney problems?
The use of Steglatro may require dose adjustments or may not be recommended in patients with severe renal impairment or end-stage renal disease [1][3].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209939s000,209940s000lbl.pdf
[2] https://www.drugpatentwatch.com/drugs/steglatro
[3] https://www.rxlist.com/steglatro-drug.htm
[4] https://www.drugpatentwatch.com
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa2003007